StocksMedium•13 October 2026•
1 min read
Liquidia and United Therapeutics Reach Global Settlement Ending All Litigation
Key Facts
1Liquidia announced a global settlement agreement with United Therapeutics resolving all pending litigation between the companies.
2The settlement ensures that YUTREPIA inhalation powder remains available to PAH patients without disruption.
Liquidia announced a global settlement agreement with United Therapeutics resolving all pending litigation between the companies, GlobeNewswire reported. The settlement ensures that YUTREPIA inhalation powder remains available to pulmonary arterial hypertension (PAH) patients without disruption.
LQDA closed at $27.67 on October 12, 2026, while UTHR closed at $550.1 on the same date. The companies entered the agreement to end protracted litigation regarding patent and commercialization rights for treprostinil-based treatments.